For accelerated designations, a clean clinical signal from a small, homogenous patient sample is more valuable than a weaker signal from a larger, more diverse group. Early cohorts should be narrowed to a uniform population representing the true unmet medical need to ensure consistency of results.

Recent failures in trials for hsCRP and Lp(a) targets highlight a growing challenge in cardiovascular R&D. Existing treatments like statins and GLP-1s have raised the standard of care so high that proving an incremental benefit for a new drug is incredibly difficult, requiring massive, expensive, and often unsuccessful studies.

AI can identify patient subgroups that respond best to a drug, but this creates a paradox. The more narrowly the group is defined, the smaller it becomes, which weakens the trial's statistical power to detect an effect. The core challenge is optimizing the trade-off between signal clarity and statistical viability.

Novartis's cardio drug failure in a secondary prevention trial highlights a critical development challenge: even for genetically-validated targets, intervening late in a chronic disease's progression may be ineffective. The damage may already be too extensive, suggesting earlier treatment is needed to show a benefit.

Progress in prostate cancer was historically challenged because trials in the 80s-2000s included a large proportion of patients with low-risk disease (e.g., Gleason 6). These patients didn't require aggressive therapy, which "contaminated" results and made it difficult to discern the true benefit of new treatments for high-risk populations.

The Harmony VI lung cancer trial's confusing inclusion/exclusion criteria for high-risk patients highlights a critical debate: developing drugs in idealized settings can limit their applicability and create uncertainty for treating the actual patients clinicians see daily.

Many clinical trials fail not because the science is wrong, but because of operational issues like patient recruitment and retention. These problems often stem from overly burdensome and rigid trial designs that deter participation, a preventable error.

Focusing solely on LDL is a mistake. Even individuals with a genetic mutation leading to lifelong low LDL levels can still have cardiovascular events if they have other unmanaged risk factors like metabolic syndrome, obesity, or diabetes, highlighting the need for a comprehensive approach.

Despite meeting its primary endpoint, the PROTEUS trial provides no validated biomarkers to identify which patients actually benefit from the intensified therapy. This lack of a predictive signature means applying the results in the clinic amounts to uniform escalation, likely overtreating many patients for an uncertain benefit, making it difficult to implement.